Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Structure/function vs. disease claims

This article was originally published in The Tan Sheet

Executive Summary

CDER is leading an agency-wide working group of roughly 20 people, including reps from CFSAN, the Office of Policy and the Office of Chief Counsel, that will develop a guidance on structure/function vs. disease claims, FDA says in a Feb. 29 letter to the dietary supplement community clarifying appropriate contacts for questions on the structure/function claims final rule. CDER has lead responsibility on disease/non-disease distinctions; correspondence should be directed to the Executive Secretariat, Executive Operations HFD-6, at (301)-594-5468. Contact point at CFSAN, which oversees the rule's implementation and enforcement, is the Division of Compliance & Enforcement within the Office of Nutritional Products, Labeling & Dietary Supplements at (202)-205-5229
Advertisement

Related Content

Topics

Advertisement
UsernamePublicRestriction

Register

PS090970

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel